In-Stent Restenosis Best Corrected With Drug-Eluting Stent

NEW YORK (Reuters Health) Aug 21
- The risk of restenosis is significantly lower when revascularization is achieved with a paclitaxel-eluting stent than by vascular brachytherapy for a bare metal stent in-stent restenosis, according to the 2-year findings of the TAXUS V-ISR multicenter trial.
Dr. Stephen G. Ellis of the Cleveland Clinic in Ohio and colleagues prospectively randomized 396 patients with a bare metal stent restenosis to receive either a Taxus stent or vascular brachytherapy treatment.

Ischemia-driven target lesion revascularization was required less frequently with the paclitaxel-eluting stent than with vascular brachytherapy, with revascularization rates of 5.3% and 10.3% at 9 to 24 months, respectively, the investigators report in the July issue of the European Heart Journal.

At 24 months, ischemia-driven target lesion revascularization was significantly reduced with paclitaxel-eluting stent, with a rate of 10.1% compared with 21.6% for vascular brachytherapy.

There were no significant differences in death, myocardial infarction, or target vessel thrombosis between the two groups after 1 or 2 years.

In an editorial, Dr. Debabrata Mukherjee of the University of Kentucky at Lexington notes that the era of bare metal stent is waning again, while the use of drug-eluting stents is once again becoming the preferred option for in-stent restenosis.

In 2007, the use of drug-eluting stents dropped because of concerns with restenosis. "We have more objective data now to support the use of drug-eluting stents. The key is the use of aspirin and clopidogrel, with their use extended for 1 year," Dr. Mukherjee commented in an interview with Reuters Health.

"The bottom line is that at this point in time, drug-eluting stents implantation (for in-stent restenosis) is best," Dr. Mukherjee asserted. "There are some exceptions, such as diffuse stenosis of the proximal (left anterior descending artery), when bypass surgery would be a better option."

"Still, about one third of patients in the US receive a bare metal stent," Dr. Mukherjee cautioned. "That's a significant population; it's about 100,000 people."

Eur Heart J 2008;29:1595-1596,1625-1634.


--------------------------------------------------------------------------------



Reuters Health Information 2008. © 2008 Reuters Ltd.

Comments

Popular posts from this blog

Inflammatory Bowel Disease an Independent Risk Factor for MI

The Council of the European Union has decided that the European Medicines Agency (EMA) will be relocated to the City of Amsterdam.

What makes prostate cancer aggressive? Or not so....Study investigates